image credit: Pexels

Mesoblast scores FDA committee’s backing for cell therapy despite some early worries

August 14, 2020

Cell and gene therapy makers have to contend with a laundry list of concerns on the road to approval, including a complicated manufacturing process and often, some regulatory pushback. Facing what was expected to be an FDA firing line over its cell therapy, Mesoblast is instead looking at a clear path to market.

Despite some pushback over its clinical data and manufacturing process, Mesoblast received a near-unanimous thumbs up Thursday for cell therapy Ryoncil from an FDA advisory committee.

The committee voted 9-1 to recommend the FDA’s approval of Ryoncil (remestemcel-L) in pediatric acute graft vs. host disease (GVHD), an indication with no approved therapies. The drug faces a full FDA review by Sept. 30.

Read More on FiercePharma